Chemo plus immunotherapy for muscle-invasive bladder cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests adding two immunotherapy drugs (cemiplimab and fianlimab) to standard chemotherapy (gemcitabine and cisplatin) for people with bladder cancer that has grown into the muscle layer but hasn't spread. The goal is to see if adding these immunotherapies helps shrink the tumor before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have bladder cancer that has grown into the muscle layer (stage T2 or T3) but hasn't spread to lymph nodes or other organs.
- You are 18 years or older and in generally good health (able to do daily activities without much help).
- You are able to receive cisplatin chemotherapy (your doctor will check this).
- You haven't had chemotherapy or immunotherapy before for this type of bladder cancer.
- You haven't had radiation therapy to the bladder or a transplant of any kind.
- You don't have an active autoimmune disease or serious infection, and you're not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (enfortumab vedotin and pembrolizumab) plus radiation therapy for people with bladder cancer that has grown into the muscle layer. The goal is to see if this treatment can kill the cancer while avoiding the need for bladder removal surgery.
This trial tests a combination of two drugs—an antibody-drug conjugate (a targeted therapy that delivers cancer-killing medicine directly to cells) and an immunotherapy that helps your immune system fight cancer. The goal is to see if this combo works better than the standard chemoradiotherapy for bladder cancer when you keep your bladder.
This trial tests a combination of a targeted drug (HDAC inhibitor, given directly into the bladder) and an immunotherapy (Durvalumab, given through a vein) before bladder removal surgery. It's for people with muscle-invasive bladder cancer who cannot take the chemo drug cisplatin.
This trial tests a new drug combination for advanced bladder or urinary tract cancer that has not been treated before. The study compares a standard chemotherapy plus immunotherapy with and without an extra drug that may reduce side effects.
This trial tests a combination of two drugs (eribulin and toripalimab) given before surgery to remove bladder cancer. The goal is to shrink the tumor and improve outcomes for people with advanced or high-risk bladder cancer.
This trial tests a combination of chemotherapy placed directly into the bladder and an immunotherapy drug called pembrolizumab (given through a vein) for people with high-risk bladder cancer that has not completely responded to or has returned after BCG treatment.
Hear when a new Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.